QUICKLINKS AND VIEW OPITONS
Metformin causes small amount of weight loss in diabetics, but considerably reduces risk of death
Tuesday, January 10, 2006 12:03 am Email this article
Glucophage (metformin) causes a small amount of weight loss on the order of a couple of pounds when given to patients with diabetes. However, it appears to considerably reduce the risk of diabetes related diseases and death compare to other diabetes treatments according to a new review. RECOMMENDED FOR LIFE EXTENSION PATIENTS
Dr. Ward Dean recommends to his life extension patients over 40
Dr. Ward Dean, MD, who I have a great deal of respect for, recommends Glucophage (metformin) to all of his life extension patients over the age of 40.
Dr. Ward Dean recommends 500 mg twice a day
He recommends that patients take 500 mg twice a day.
Take with food
Comment: In my experience, it is best taken with food.
MOST POTENT LIFE EXTENSION DRUG?
Metformin’s stronger cousin most potent life extension drug available
Dr. Dean has said that Vladamir Dilman, a famous Russian gerentologist, believed that phenformin, metformin’s stronger cousin which was removed from the market due to serious adverse effects in a small number of patients, was the most effective life-extending drug known.
REDUCES DEATH AND DISEASE
Metformin reduced risk of death and disease
The current review paper found that Glucophage (metformin) considerably reduced the risk of disease and death in patients compared to other treatments.
The amount of reduction seen in patients given Glucophage (metformin) compared to those given other forms of treatment including sulphonylureas or insulin is as follows:
- 22% reduction of any diabetes-related outcome
- 24% reduction in the risk of diabetes-related death, however, the difference did not reach statistical significance
- 27% reduction in the risk of death by any cause
- 22% reduction in the risk of having a heart attack, however, the difference did not reach statistical significance
- 44% reduction in the risk of having a stroke
- 39% increase in the risk of peripheral vascular disease, that is damage to or blockage in the veins that carry blood from your arms and legs back to your heart, however, the difference was not statistical significance
- 10% reduction in the risk of microvascular disease, that is damage to small blood vessels that sometimes occurs when a person has had diabetes for a long time, however, the difference was not statistical significance
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005, (3):CD002966.
AUTHOR’S CONTACT INFORMATION
Centro de Salud Pozuelo 1
INSALUD - Madrid, Spain
Pozuelo de Alarcon
Madrid, Spain, 28224
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.